NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo

Neurobiology of Disease
Yingjie QiMichael J Rowan

Abstract

Pro-inflammatory mechanisms have recently emerged as an important component of early Alzheimer's disease (AD) pathogenesis. A particularly attractive therapeutic strategy is to selectively prevent the disruptive effects of activation of the innate immune system in the brain at an early transitional stage by reducing the production or directly neutralizing pro-inflammatory cytokines, in particular IL-1β and TNF-α. Here we tested their in vivo effects on synaptic plasticity deficits, which provide sensitive and robust measures of synaptic failure, in a rat model of AD amyloidosis. Using electrophysiological techniques we longitudinally studied the effects of the NLRP3 inflammasome inhibitor Mcc950, the IL-1 receptor antagonist (anakinra) and an anti-TNF-α agent (etanercept) in awake freely moving transgenic rats overexpressing AD associated β-amyloid precursor protein at a pre-plaque stage of amyloidosis. Repeated treatment with Mcc950 reversibly abrogated the inhibition of long-term potentiation. The IL-1 receptor antagonist and etanercept also had a similar beneficial effect on the deficit in synaptic plasticity. Our findings support the clinical development of Mcc950 and clinically available IL-1- and TNF-α-neutralizing agents...Continue Reading

Citations

Feb 7, 2019·Journal of Leukocyte Biology·Shoutang Wang, Marco Colonna
Feb 13, 2020·International Journal of Molecular Sciences·So Yeong CheonBon-Nyeo Koo
Dec 20, 2018·Frontiers in Neurology·Adonis SferaCarolina Osorio
Mar 20, 2019·Frontiers in Pharmacology·A Claudio CuelloSonia Do Carmo
Dec 19, 2018·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Qing-Guo RenZhi-Jun Zhang
Sep 21, 2018·Frontiers in Molecular Neuroscience·Bo-Zong ShaoChong Liu
Jul 13, 2019·Frontiers in Aging Neuroscience·Carolina OsorioAdonis Sfera
Apr 1, 2020·Journal of the American Heart Association·Pingping RenScott A LeMaire
Aug 6, 2020·International Journal of Molecular Sciences·Jin-Seok LeeChang-Gue Son
Jan 28, 2021·Neurochemistry International·Sukanya Sarkar, Subhas C Biswas
Jun 3, 2021·International Journal of Molecular Sciences·Anna LitwiniukAgnieszka Baranowska-Bik
Jul 1, 2021·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yingjie QiMichael J Rowan
Aug 14, 2021·Metabolic Brain Disease·Awanish MishraNavneet Khurana
Jan 16, 2022·Drug Discovery Today·Pieter DujardinLien Van Hoecke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.